Prosecution Insights
Last updated: April 19, 2026
Application No. 17/083,078

SYSTEMS AND METHODS FOR PROCESSING SONIFIED BRAIN SIGNALS

Final Rejection §101
Filed
Oct 28, 2020
Examiner
TU, AURELIE H
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Ceribell Inc.
OA Round
6 (Final)
56%
Grant Probability
Moderate
7-8
OA Rounds
3y 9m
To Grant
99%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allow Rate
126 granted / 227 resolved
-14.5% vs TC avg
Strong +62% interview lift
Without
With
+62.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
61 currently pending
Career history
288
Total Applications
across all art units

Statute-Specific Performance

§101
20.9%
-19.1% vs TC avg
§103
30.9%
-9.1% vs TC avg
§102
15.7%
-24.3% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 227 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Claims 2, 8, 12, 19, and 23-32 are currently pending. Claims 7, 9, 17, 18, and 20 have been cancelled. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 2, 8, 12, 19, and 23-32 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) as a whole, considering all claim elements both individually and in combination, do not amount to significantly more than an abstract idea. A streamlined analysis of claim 2 follows. STEP 1 Regarding claim 2, the claim recites a series of steps or acts, including transmitting one or more time-domain signals from one or more EEG sensors worn by the living subject to a signal modulator of a digital processor. Thus, the claim is directed to a process, which is one of the statutory categories of invention. STEP 2A, PRONG ONE The claim is then analyzed to determine whether it is directed to any judicial exception. The steps of: transforming the one or more time-domain signals into a measurement acoustic signal resembling one or more of a vocal pattern and a vocal parameter of a human voice using the signal modulator; audibly providing the human voice over one or more speakers; accessing, via a user interface, a database comprising a plurality of comparison acoustic signals; and comparing the measurement acoustic signal to the one or more of a plurality of comparison acoustic signals, each of the plurality of comparison acoustic signals resembling one or more of a vocal pattern and a vocal parameter of a human voice set forth a judicial exception. These steps describe a concept performed in the human mind (including an observation, evaluation, judgment, opinion). Thus, the claim is drawn to a Mental Process, which is an Abstract Idea. The transforming step is also a mathematical process, which is also an Abstract Idea. Furthermore, the providing and accessing step is also organizing human activity, which is also an Abstract Idea. STEP 2A, PRONG TWO Next, the claim as a whole is analyzed to determine whether the claim recites additional elements that integrate the judicial exception into a practical application. The claim fails to recite an additional element or a combination of additional elements to apply, rely on, or use the judicial exception in a manner that imposes a meaningful limitation on the judicial exception. Claim 2 recites detecting seizure activity when at least a volume of the human voice increase based on the comparison, which is merely adding insignificant extra-solution activity to the judicial exception (MPEP 2106.05(g)). The detected seizure activity does not provide an improvement to the technological field, the method does not effect a particular treatment or effect a particular change based on the detected seizure activity, nor does the method use a particular machine to perform the Abstract Idea. STEP 2B Next, the claim as a whole is analyzed to determine whether any element, or combination of elements, is sufficient to ensure that the claim amounts to significantly more than the exception. Besides the Abstract Idea, the claim recites the additional step of including transmitting one or more time-domain signals from one or more EEG sensors worn by the living subject to a signal modulator of a digital processor, the one or more time-domain signals representing brain activity of the living subject. Transmitting data (time-domain signals) is well-understood, routine and conventional activity for those in the field of medical diagnostics as [0014] of Pless et al. ‘428 (US Pub No. 2003/0004428 – previously cited) teaches that it is typical to use EEG signals received from electrodes in a time-domain detection system. Further, the transmitting step is recited at a high level of generality such that it amounts to insignificant presolution activity, e.g., mere data gathering step necessary to perform the Abstract Idea. When recited at this high level of generality, there is no meaningful limitation, such as a particular or unconventional step that distinguishes it from well-understood, routine, and conventional data gathering activity engaged in by medical professionals prior to Applicant's invention. Furthermore, it is well established that the mere physical or tangible nature of additional elements such as the obtaining step does not automatically confer eligibility on a claim directed to an abstract idea (see, e.g., Alice Corp. v. CLS Bank Int'l, 134 S.Ct. 2347, 2358-59 (2014)). Consideration of the additional elements as a combination also adds no other meaningful limitations to the exception not already present when the elements are considered separately. Unlike the eligible claim in Diehr in which the elements limiting the exception are individually conventional, but taken together act in concert to improve a technical field, the claim here does not provide an improvement to the technical field. Even when viewed as a combination, the additional elements fail to transform the exception into a patent-eligible application of that exception. Thus, the claim as a whole does not amount to significantly more than the exception itself. The claim is therefore drawn to non-statutory subject matter. The same rationale applies to claim 12. Regarding claim 12, the device recited in the claim is a generic device comprising generic components configured to perform the abstract idea. The recited EEG sensor are generic sensors configured to perform the pre-solution activity of data gathering. The recited database and the recited memory are generic devices configured to perform WURC data storing and the one or more processors is configured to perform the Abstract Idea. According to section 2106.05(f) of the MPEP, merely using a computer as a tool to perform an abstract idea does not integrate the Abstract Idea into a practical application. The dependent claims also fail to add something more to the abstract independent claims. Claims 23 and 24 are merely further defining the generic computer components as WURC components. Claims 25-32 recite what the vocal patterns of the transformed measurement acoustic signal and the transformed comparison acoustic signal are, which does not add anything significantly more to the abstract idea. However, it is noted that claims 8 and 19 recite “wherein the feedback therapy is based on the one or more audibly distinct variations of the transformed measurement acoustic signal.” This provides more detail as to when the feedback therapy or the determination of the activity of the organ is provided. However, it is unclear what exact criteria is needed for the one or more audibly distinct variations of the measurement acoustic signal in order to provide the therapy or the determination of the activity. Section 2106.04(d)(2) of the MPEP mentions that “treating a patient having a blood glucose Response to Arguments Applicant argues that the comparison step provides specific criteria for the sonified signals to determine seizure activity based on the change in volume of the human voice supports a practical application and that the change in volume may allow improved detection of seizure activity. However, the comparison step is a mental process, which is an Abstract Idea. Furthermore, the change in volume of the human voice is based on the comparison is also a mental process (MPEP 2106.04(a)(2) III. A. mentions that analyzing/comparing data and displaying certain results of the collection and analysis is a mental process). It is noted that section 2106.05(a) II. of the MPEP states that “…it is important to keep in mind that an improvement in the abstract idea itself (e.g. a recited fundamental economic concept) is not an improvement in technology.” As such, Applicant’s arguments are not persuasive and the 35 U.S.C. 101 rejection has been maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AURELIE H TU whose telephone number is (571)272-8465. The examiner can normally be reached [M-F] 7:30-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at (571) 272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AURELIE H TU/ Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Oct 28, 2020
Application Filed
Jan 12, 2023
Non-Final Rejection — §101
Jul 18, 2023
Response Filed
Aug 09, 2023
Final Rejection — §101
Feb 12, 2024
Request for Continued Examination
Feb 22, 2024
Response after Non-Final Action
Apr 01, 2024
Non-Final Rejection — §101
Jul 03, 2024
Response Filed
Aug 30, 2024
Final Rejection — §101
Mar 05, 2025
Request for Continued Examination
Mar 06, 2025
Response after Non-Final Action
Apr 08, 2025
Non-Final Rejection — §101
Oct 10, 2025
Response Filed
Dec 08, 2025
Final Rejection — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593995
A BLOOD PRESSURE MEASURING DEVICE
2y 5m to grant Granted Apr 07, 2026
Patent 12593992
SPHYGMOMANOMETER, PERSONAL AUTHENTICATION METHOD ON A SPHYGMOMANOMETER, AND COMPUTER-READABLE RECORDING MEDIUM
2y 5m to grant Granted Apr 07, 2026
Patent 12591305
INTELLIGENT HUMAN-MACHINE INTERFACE AND METHOD WHICH CAN BE CARRIED OUT USING SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12588869
METHOD AND APPARATUS PROVIDING AN ONGOING AND REAL TIME INDICATOR FOR SURVIVAL AND MAJOR MEDICAL EVENTS
2y 5m to grant Granted Mar 31, 2026
Patent 12575788
SYSTEMS, METHODS, APPARATUSES, AND DEVICES FOR FACILITATING TREATMENT FOR ANORECTAL AND PELVIC FLOOR DISORDERS OF USERS USING BIOFEEDBACK THERAPY
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
56%
Grant Probability
99%
With Interview (+62.1%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 227 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month